Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

Shares of IRMD stock opened at $91.12 on Thursday. The firm’s 50 day moving average price is $91.36 and its 200-day moving average price is $95.54. iRadimed Corporation has a one year low of $55.11 and a one year high of $107.90. The firm has a market cap of $1.16 billion, a P/E ratio of 49.79 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, research analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. iRadimed’s dividend payout ratio is presently 43.72%.

Institutional Investors Weigh In On iRadimed

A number of large investors have recently modified their holdings of IRMD. T. Rowe Price Investment Management Inc. increased its position in shares of iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after purchasing an additional 55,426 shares during the last quarter. Informed Momentum Co LLC purchased a new stake in shares of iRadimed in the 4th quarter valued at approximately $5,361,000. SG Americas Securities LLC increased its position in shares of iRadimed by 88.6% in the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after purchasing an additional 33,072 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of iRadimed by 473.9% in the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after purchasing an additional 29,010 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IRMD has been the topic of several recent research reports. Lake Street Capital reaffirmed a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Roth Mkm reaffirmed a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. Finally, Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.